Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Obstetricians' and gynecologists' knowledge, education, and practices regarding chronic hepatitis B in pregnancy.

Niu B, Marzio DH, Fenkel JM, Herrine SK.

Ann Gastroenterol. 2017;30(6):670-674. doi: 10.20524/aog.2017.0196. Epub 2017 Sep 30.

2.

American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease.

Herrine SK, Moayyedi P, Brown RS Jr, Falck-Ytter YT.

Gastroenterology. 2017 Feb;152(3):648-664.e5. doi: 10.1053/j.gastro.2016.12.027. Epub 2017 Jan 4. No abstract available.

PMID:
28061338
3.

Hepatocellular carcinoma after locoregional therapy: Magnetic resonance imaging findings in falsely negative exams.

Becker-Weidman D, Civan JM, Deshmukh SP, Roth CG, Herrine SK, Parker L, Mitchell DG.

World J Hepatol. 2016 Jun 8;8(16):685-90. doi: 10.4254/wjh.v8.i16.685.

4.

A Clinical Decision Rule Based on the AST-to-Platelet Ratio Index Improves Adherence to Published Guidelines on the Management of Acute Variceal Bleeding.

Civan JM, Lindenmeyer CC, Whitsett M, Herrine SK.

J Clin Gastroenterol. 2015 Aug;49(7):599-606. doi: 10.1097/MCG.0000000000000173.

PMID:
26167719
5.

Training directors have positive perceptions of a competency-based gastroenterology and transplant hepatology fellowship program.

Halegoua-De Marzio DL, Herrine SK.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):398-401.e3. doi: 10.1016/j.cgh.2014.07.053. Epub 2014 Aug 9.

PMID:
25111235
6.

Patterns of acetaminophen use exceeding 4 grams daily in a hospitalized population at a tertiary care center.

Civan JM, Navarro V, Herrine SK, Riggio JM, Adams P, Rossi S.

Gastroenterol Hepatol (N Y). 2014 Jan;10(1):27-34.

7.

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators.

Gastroenterology. 2013 Nov;145(5):1035-1044.e5. doi: 10.1053/j.gastro.2013.07.051. Epub 2013 Aug 4.

PMID:
23924660
8.

Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study.

Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Herrine SK, Stevens M, Schmitt J, Rehermann B.

J Infect Dis. 2013 Sep;208(6):1020-5. doi: 10.1093/infdis/jit270. Epub 2013 Jun 24.

9.

Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma.

Petruzzi NJ, Frangos AJ, Fenkel JM, Herrine SK, Hann HW, Rossi S, Rosato EL, Eschelman DJ, Gonsalves CF, Brown DB.

J Vasc Interv Radiol. 2013 Feb;24(2):266-73. doi: 10.1016/j.jvir.2012.10.025. Epub 2012 Dec 20.

PMID:
23261143
10.

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators.

Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11.

PMID:
23081753
11.

Racial differences in hepatitis C treatment eligibility.

Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team.

Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358.

12.

Boceprevir for previously treated chronic HCV genotype 1 infection.

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.

13.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

14.

The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes.

Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T.

Aliment Pharmacol Ther. 2011 Mar;33(5):559-65. doi: 10.1111/j.1365-2036.2010.04549.x. Epub 2010 Dec 29.

15.

Image of the month. Fulminant hepatic failure caused by Amanita phalloides toxicity.

Cress CM, Malliah A, Herrine SK.

Clin Gastroenterol Hepatol. 2011 Feb;9(2):A26. doi: 10.1016/j.cgh.2010.08.012. Epub 2010 Oct 16. No abstract available.

PMID:
20816861
16.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team.

Gastroenterology. 2010 Nov;139(5):1602-11, 1611.e1. doi: 10.1053/j.gastro.2010.07.059. Epub 2010 Aug 16.

PMID:
20723545
17.

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team.

Gastroenterology. 2010 Oct;139(4):1267-76. doi: 10.1053/j.gastro.2010.06.062. Epub 2010 Jul 1.

18.

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team.

Gastroenterology. 2010 Oct;139(4):1257-66. doi: 10.1053/j.gastro.2010.06.066. Epub 2010 Jun 27.

PMID:
20600013
19.

Making the best of a bad situation: early chronic nosocomial HCV infection.

Santos C, Herrine SK.

Dig Dis Sci. 2010 Jun;55(6):1509-11. doi: 10.1007/s10620-010-1283-5. Epub 2010 May 18. No abstract available.

PMID:
20480237
20.

Over-the-counter analgesics in cirrhotic patients: a case-control study examining the risk of hospitalization for liver-associated events.

Fenkel JM, Coron RN, Daskalakis C, Vega M, Rossi S, Herrine SK, Navarro VJ.

Scand J Gastroenterol. 2010 Sep;45(9):1101-9. doi: 10.3109/00365521003663704.

PMID:
20230184

Supplemental Content

Loading ...
Support Center